Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180051 | 0.93 | GRM5 (0.59) | GRM5NPC1RAB9AKMT2AGAA | |
| SCHEMBL4180036 | 0.91 | GRM5 (0.60) | GRM5KCNH2 | |
| SCHEMBL4171869 | 0.88 | GRM5 (0.66) | GRM5KCNH2GAAMAPTTSHR | |
| SCHEMBL4172582 | 0.85 | GRM5 (0.64) | GRM5KCNH2GAATSHR | |
| SCHEMBL4173204 | 0.83 | GRM5 (0.60) | GRM5GAATSHR | |
| SCHEMBL4172348 | 0.80 | GRM5 (0.67) | GRM5KCNH2NPC1RAB9A | |
| SCHEMBL2895294 | 0.77 | GRM5 (0.73) | GRM5KCNH2KMT2AMAPK1 | |
| SCHEMBL2895291 | 0.77 | GRM5 (0.73) | GRM5KCNH2KMT2AMAPK1 | |
| SCHEMBL2895780 | 0.77 | GRM5 (0.73) | GRM5KCNH2KMT2AMAPK1 | |
| SCHEMBL4162387 | 0.77 | GRM5 (0.62) | GRM5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1573/4885GABRA5 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.